Tetsuya Mitsudomi
#108,520
Most Influential Person Now
Researcher
Tetsuya Mitsudomi's AcademicInfluence.com Rankings
Tetsuya Mitsudomiphilosophy Degrees
Philosophy
#4482
World Rank
#7015
Historical Rank
Logic
#1921
World Rank
#2793
Historical Rank
Download Badge
Philosophy
Tetsuya Mitsudomi's Degrees
- Doctorate Medicine University of Tokyo
- PhD Medicine University of Tokyo
Why Is Tetsuya Mitsudomi Influential?
(Suggest an Edit or Addition)Tetsuya Mitsudomi's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. (2010) (3811)
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling (2007) (3564)
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (2011) (3193)
- Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival (2004) (2492)
- Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer (2004) (1215)
- EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. (2010) (1142)
- Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. (2005) (938)
- Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. (1998) (897)
- Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial (2017) (650)
- Reduced expression of Dicer associated with poor prognosis in lung cancer patients (2005) (638)
- Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. (2008) (616)
- Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib (2006) (611)
- Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer (2007) (587)
- Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. (1990) (559)
- Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. (2016) (506)
- Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer (2010) (478)
- p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. (1992) (475)
- A Prospective Radiological Study of Thin-Section Computed Tomography to Predict Pathological Noninvasiveness in Peripheral Clinical IA Lung Cancer (Japan Clinical Oncology Group 0201) (2011) (421)
- TTF-1 Expression in Pulmonary Adenocarcinomas (2002) (354)
- Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. (1999) (339)
- Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. (2000) (335)
- Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. (1991) (328)
- Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. (2016) (322)
- The Increasing Dominance of Teams in Production of Knowledge (2011) (317)
- Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. (1992) (311)
- Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. (2006) (310)
- Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. (2000) (292)
- Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers (2009) (289)
- Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia (2012) (277)
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. (2022) (276)
- ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. (1991) (263)
- Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy (2016) (262)
- Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. (2015) (248)
- Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial. (2019) (241)
- High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. (1992) (236)
- Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib (2011) (236)
- Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. (1996) (235)
- Radiographically determined noninvasive adenocarcinoma of the lung: survival outcomes of Japan Clinical Oncology Group 0201. (2013) (233)
- EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma (2005) (231)
- Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. (1993) (230)
- Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment (2017) (229)
- Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer (2017) (228)
- Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma (2009) (226)
- Predictors of Survival in Patients With Bone Metastasis of Lung Cancer (2008) (223)
- Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. (2011) (221)
- Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. (2014) (217)
- Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer (2010) (203)
- Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation (2010) (202)
- Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients (2004) (202)
- Biological and clinical implications of EGFR mutations in lung cancer (2006) (201)
- Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations (2009) (197)
- Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. (1992) (194)
- A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. (2006) (192)
- Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. (1990) (190)
- Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. (2009) (190)
- Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival (2017) (189)
- Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. (1991) (189)
- Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. (1993) (189)
- CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials (2017) (185)
- Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. (2008) (174)
- The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. (2016) (174)
- Mutations in the p53 gene in primary human breast cancers. (1991) (173)
- EGFR T790M mutation: a double role in lung cancer cell survival? (2009) (171)
- Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer (2007) (169)
- Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. (2004) (167)
- Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. (2007) (165)
- Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial (2022) (164)
- EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs (2015) (160)
- Surgical implications of the new IASLC/ATS/ERS adenocarcinoma classification (2011) (159)
- Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer (2008) (159)
- Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). (2012) (159)
- Polymorphism at codon 213 within the p53 gene. (1991) (156)
- K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. (1997) (152)
- Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients (2004) (147)
- Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS (2019) (146)
- Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk. (2004) (145)
- Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. (2011) (139)
- Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). (2016) (137)
- Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. (2008) (135)
- p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. (1994) (134)
- Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation—diversity, ductility, and destiny (2012) (134)
- Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. (2015) (133)
- IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY. (2020) (132)
- Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib (2009) (132)
- NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese (2002) (127)
- EGFR mutation and response of lung cancer to gefitinib. (2005) (123)
- Impact of EGFR mutation analysis in non-small cell lung cancer. (2009) (122)
- Epidermal growth factor receptor inhibition in lung cancer: status 2012. (2013) (119)
- Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. (1996) (119)
- [Molecular abnormalities in lung cancer]. (2002) (118)
- Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation (2012) (118)
- Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas (2007) (117)
- p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. (1998) (116)
- Surgical treatment of lung cancer in the octogenarian. (1994) (114)
- Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer (2010) (113)
- Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies (2018) (113)
- Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort (2011) (111)
- Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study. (2016) (110)
- Molecular Diagnosis of Activating EGFR Mutations in Non–Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis (2010) (109)
- Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. (1996) (109)
- A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903) (2012) (107)
- A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study). (2015) (106)
- Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? (2007) (106)
- The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification (2009) (104)
- Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers (2002) (104)
- Advances in target therapy for lung cancer. (2010) (103)
- Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. (1992) (103)
- Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station. (2001) (102)
- Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. (2012) (102)
- Dietary factors and lung cancer risk in Japanese: with special reference to fish consumption and adenocarcinomas (2001) (101)
- Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer (2006) (98)
- Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected? (2013) (95)
- Genomic profiling of malignant pleural mesothelioma with array‐based comparative genomic hybridization shows frequent non‐random chromosomal alteration regions including JUN amplification on 1p32 (2007) (95)
- Expression of cancer/testis (CT) antigens in lung cancer. (2003) (92)
- An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. (2012) (91)
- Osimertinib (AZD9291) in pre‐treated pts with T790M‐positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results: LBA2_PR (2016) (91)
- PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients (2006) (90)
- Effect of selective lymph node dissection based on patterns of lobe-specific lymph node metastases on patient outcome in patients with resectable non-small cell lung cancer: a large-scale retrospective cohort study applying a propensity score. (2010) (90)
- The Impact of Sex and Smoking Status on the Mutational Spectrum of Epidermal Growth Factor Receptor Gene in Non–small Cell Lung Cancer (2007) (89)
- EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. (2006) (89)
- Risk factors differ for non‐small‐cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case‐control study in Japanese (2007) (88)
- Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP1A1 genotypes in Japanese (1995) (88)
- Relationship between early recurrence and micrometastases in the lymph nodes of patients with stage I non-small-cell lung cancer. (1997) (87)
- Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. (2001) (87)
- CK20 expression, CDX2 expression, K‐ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas (2004) (86)
- A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study) (2016) (85)
- A limited association of OGG1 Ser326Cys polymorphism for adenocarcinoma of the lung. (2002) (85)
- Surgery for NSCLC in the era of personalized medicine (2013) (84)
- A Screening Method for the ALK Fusion Gene in NSCLC (2012) (84)
- Epidermal growth factor receptor mutations in lung cancers (2007) (83)
- High frequency of clonally related tumors in cases of multiple synchronous lung cancers as revealed by molecular diagnosis. (2000) (83)
- Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations. (2014) (81)
- CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. (2014) (81)
- How Long Should Small Lung Lesions of Ground-Glass Opacity be Followed? (2013) (80)
- Lung cancer in never smokers: change of a mindset in the molecular era. (2011) (79)
- Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. (1996) (79)
- KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from the in vitro experiments. (2021) (79)
- Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro. (2019) (79)
- Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer (2012) (79)
- Impact of one-carbon metabolism-related gene polymorphisms on risk of lung cancer in Japan: a case control study. (2007) (78)
- Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer. (1997) (78)
- A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. (2007) (76)
- Carcinosarcoma and spindle cell carcinoma of the lung. Clinicopathologic and immunohistochemical studies. (1990) (76)
- Molecular oncology of lung cancer (2011) (75)
- Association of a polymorphism of the phospholipase D2 gene with the prevalence of colorectal cancer (2003) (75)
- Maximum length of tracheal autografts in dogs. (1993) (74)
- Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). (2021) (74)
- HNF4&agr; as a Marker for Invasive Mucinous Adenocarcinoma of the Lung (2013) (74)
- Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor? (2016) (74)
- Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer (2015) (73)
- The association between baseline clinical-radiological characteristics and growth of pulmonary nodules with ground-glass opacity. (2014) (72)
- Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. (1997) (72)
- Postoperative complications after pneumonectomy for treatment of lung cancer: Multivariate analysis (1996) (72)
- A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer. (2020) (72)
- Inflammatory pseudotumor of the lung in adults: radiographic and clinicopathological analysis. (1989) (72)
- Increased Prevalence of EGFR-Mutant Lung Cancer in Women and in East Asian Populations: Analysis of Estrogen-Related Polymorphisms (2008) (70)
- Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. (2019) (68)
- Mutations of epidermal growth factor receptor and K‐ras genes in adenosquamous carcinoma of the lung (2006) (68)
- Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer. (2015) (67)
- p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival. (1995) (67)
- The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status. (2003) (66)
- Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never‐smoking women in Asia: a report from the female lung cancer consortium in Asia (2015) (64)
- Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. (1997) (63)
- Testing for COVID-19 in lung cancer patients (2020) (63)
- Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. (2019) (62)
- Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation (2004) (60)
- Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer (2016) (59)
- EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR and KRAS Mutations in a Japanese Cohort (2009) (58)
- Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth. (2015) (58)
- Salvage surgery for advanced non-small cell lung cancer after response to gefitinib. (2010) (58)
- Prognostic Significance of p 53 Alterations in Patients with Non-Small Cell Lung Cancer : A Meta-Analysis 1 (2000) (57)
- Mutations of the P53 tumor suppressor gene as clonal marker for multiple primary lung cancers. (1997) (57)
- Frequent allelic imbalance suggests involvement of a tumor suppressor gene at 1p36 in the pathogenesis of human lung cancers (2000) (56)
- Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers (1998) (56)
- Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation. (2001) (55)
- A clinicopathological study of synchronous multiple gastric cancer (1989) (55)
- RASSF1A gene inactivation in non‐small cell lung cancer and its clinical implication (2003) (55)
- Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. (2018) (54)
- Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma. (2017) (54)
- Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. (2012) (54)
- Personalized therapy on the horizon for squamous cell carcinoma of the lung. (2013) (54)
- Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. (1995) (53)
- Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations (2016) (53)
- Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer. (1998) (53)
- Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study. (2018) (52)
- Significant up-regulation of a novel gene, CLCP1, in a highly metastatic lung cancer subline as well as in lung cancers in vivo (2002) (51)
- Identification of a metastasis signature and the DLX4 homeobox protein as a regulator of metastasis by combined transcriptome approach (2007) (50)
- Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial (2021) (49)
- 1173OMAGRIT, A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF THE RECMAGE-A3 + AS15 CANCER IMMUNOTHERAPEUTIC AS ADJUVANT THERAPY IN PATIENTS WITH RESECTED MAGE-A3-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC). (2014) (49)
- Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib (2007) (49)
- The insulin‐like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild‐type epidermal growth factor receptor (2014) (48)
- Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC). (2019) (48)
- Longer survival after resection of non-small cell lung cancer in Japanese women. (1989) (48)
- Molecular genetic characterization of neuroendocrine lung cancer cell lines. (1995) (45)
- Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypes. (2003) (45)
- Efficiency of serum copper/zinc ratio for differential diagnosis of patients with and without lung cancer (1994) (44)
- A prematurely terminated phase III trial of intraoperative intrapleural hypotonic cisplatin treatment in patients with resected non-small cell lung cancer with positive pleural lavage cytology: the incidence of carcinomatous pleuritis after surgical intervention. (2002) (44)
- Expression of human telomerase subunit genes in primary lung cancer and its clinical significance. (2000) (43)
- Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer. (2020) (42)
- Absence of hereditary p53 mutations in 10 familial leukemia pedigrees. (1992) (42)
- DIFFERENCES IN PROLIFERATION PROPERTIES AMONG SUBLINES OF RAT 3Y1 FIBROBLASTS TRANSFORMED BY VARIOUS AGENTS IN VITRO (1988) (41)
- hOGG1 Ser326Cys polymorphism and risk of lung cancer by histological type (2009) (41)
- Impact of age on epidermal growth factor receptor mutation in lung cancer. (2012) (41)
- Impact of smoking on lung cancer risk is stronger in those with the homozygous aldehyde dehydrogenase 2 null allele in a Japanese population. (2010) (41)
- A clinicopathological study of gastric cancer with special reference to age of the patients: An analysis of 1,630 cases (1989) (41)
- A nonrandomized confirmatory phase III study of sublobar surgical resection for peripheral ground glass opacity dominant lung cancer defined with thoracic thin-section computed tomography (JCOG0804/WJOG4507L). (2017) (40)
- Ground-glass nodules of the lung in never-smokers and smokers: clinical and genetic insights. (2018) (40)
- A novel germline p53 splicing mutation in a pediatric patient with a second malignant neoplasm. (1993) (39)
- Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies. (2013) (38)
- Clinical impacts of EGFR mutation status: analysis of 5,780 surgically resected lung cancer cases. (2020) (38)
- Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. (2016) (38)
- Association between a Genome-Wide Association Study-Identified Locus and the Risk of Lung Cancer in Japanese Population (2012) (38)
- MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. (1999) (38)
- Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro. (2018) (37)
- LKB1 gene mutations in Japanese lung cancer patients (2007) (37)
- 3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies (2015) (37)
- Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib (2016) (36)
- Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells. (2017) (36)
- Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis (2012) (36)
- Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer. (2010) (36)
- Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers (2008) (36)
- Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity (2015) (36)
- N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation. (1997) (35)
- Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth. (2015) (35)
- Successes and limitations of targeted cancer therapy in lung cancer. (2014) (35)
- Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer. (2016) (35)
- Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib‐treated patients with lung adenocarcinoma (2008) (35)
- Impact of bevacizumab in combination with erlotinib on EGFR‐mutated non–small cell lung cancer xenograft models with T790M mutation or MET amplification (2016) (35)
- Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. (2013) (35)
- Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small cell lung cancer. (2019) (34)
- Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses. (2009) (34)
- Brain metastases in oncogene-driven non-small cell lung cancer. (2019) (33)
- p53 mutations in non-small-cell lung cancers occurring in individuals without a past history of active smoking. (1998) (33)
- Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405). (2013) (33)
- Prognostic models in patients with non‐small‐cell lung cancer using artificial neural networks in comparison with logistic regression (2003) (33)
- Population-based mapping of pulmonary adenoma susceptibility 1 locus. (2000) (32)
- EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib (2018) (32)
- Paravertebral block via the surgical field versus epidural block for patients undergoing thoracotomy: a randomized clinical trial (2013) (32)
- Outcomes After Hepatic and Pulmonary Metastasectomies Compared With Pulmonary Metastasectomy Alone in Patients With Colorectal Cancer Metastasis to Liver and Lungs (2013) (32)
- Prognostic implication of transforming growth factor alpha in adenocarcinoma of the lung--an immunohistochemical study. (1991) (32)
- Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation (IMPACT) (2021) (31)
- FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib (2016) (31)
- Clinicopathological features of small-sized non-small cell lung cancer with mediastinal lymph node metastasis. (2009) (30)
- Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor in lung cancer (2016) (30)
- Decreased expression of 14-3-3σ in neuroendocrine tumors is independent of origin and malignant potential (2002) (30)
- Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer? (2011) (29)
- Kinetic analysis of recurrence and survival after potentially curative resection of nonsmall cell lung cancer (1996) (29)
- Soy consumption reduces the risk of non‐small‐cell lung cancers with epidermal growth factor receptor mutations among Japanese (2008) (29)
- Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A (2017) (29)
- MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor. (2015) (29)
- Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer. (1998) (29)
- Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non-small cell lung cancers. (2008) (28)
- The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations (2010) (28)
- Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms (2017) (28)
- Selective cytotoxicity of phospholipids and diacylglycerols to rat 3Y1 fibroblasts transformed by adenovirus type 12 or its E1A gene. (1988) (28)
- CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer (2018) (27)
- Primary Double‐Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench (2017) (27)
- Feasibility and efficacy of salvage lung resection after definitive chemoradiation therapy for Stage III non-small-cell lung cancer. (2016) (27)
- Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision‐Making for Patients with Advanced Solid Tumors (2020) (27)
- Topographical distributions of allelic loss in individual non-small-cell lung cancers. (2000) (26)
- ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer. (2022) (26)
- Interferon‐γ differentially regulates susceptibility of lung cancer cells to telomerase‐specific cytotoxic T lymphocytes (2004) (26)
- Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations (2013) (25)
- Fluid drainage and air evacuation characteristics of Blake and conventional drains used after pulmonary resection. (2009) (25)
- Large cell carcinoma of the lung. Prognostic implications of histopathologic and immunohistochemical subtyping. (1990) (25)
- MA16.11 CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC: Pooled Data from Two Phase II Trials (2017) (25)
- Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer (2020) (24)
- Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for 13 Cancer Types (2015) (24)
- Prognostic value and clinicopathological correlation of thrombomodulin in squamous cell carcinoma of the human lung. (1996) (24)
- Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. (2019) (24)
- Lung cancers unrelated to smoking: characterized by single oncogene addiction? (2011) (23)
- The novel one-step nucleic acid amplification (OSNA) assay for the diagnosis of lymph node metastasis in patients with non-small cell lung cancer (NSCLC): Results of a multicenter prospective study. (2016) (23)
- Novel metastasis-related gene CIM functions in the regulation of multiple cellular stress-response pathways. (2010) (22)
- Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. (2017) (22)
- Preoperative evaluation of the depth of chest wall invasion and the extent of combined resections in lung cancer patients. (2009) (22)
- fos oncogene transfer to a transformed rat fibroblast cell line enhances spontaneous lung metastasis in rat. (1986) (22)
- Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis (2019) (21)
- Molecular biological markers and micrometastasis in resected non-small-cell lung cancer. Prognostic implications. (2001) (21)
- Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naïve ALK fusion positive non-small cell lung cancer (ALK+ NSCLC). (2017) (21)
- Patterns of recurrence and outcome in patients with surgically resected small cell lung cancer (2012) (20)
- Throwing new light on lung cancer pathogenesis: Updates on three recent topics (2005) (20)
- Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges (2021) (20)
- Polymorphism at codon 36 of the p53 gene. (1994) (20)
- Invasive human fibrosarcoma DNA mediated induction of a 92 kDa gelatinase/type IV collagenase leads to an invasive phenotype. (1991) (20)
- Subcategorization of lung cancer based on tumor size and degree of visceral pleural invasion. (2008) (20)
- MEK inhibitors against MET-amplified non-small cell lung cancer (2016) (20)
- Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation (2017) (20)
- Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment‐Naïve Lesions (2017) (19)
- Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation. (2009) (19)
- Lung cancer working group report. (2010) (19)
- Identification of MGB1 as a marker in the differential diagnosis of lung tumors in patients with a history of breast cancer by analysis of publicly available SAGE data. (2004) (19)
- P1.18-02 The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC (2019) (19)
- Small peripheral lung adenocarcinoma: Clinicopathological features and surgical treatment (2010) (19)
- Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II–IIIA Non–Small Cell Lung Cancer (2015) (19)
- p53 alteration, proliferating cell nuclear antigen, and nucleolar organizer regions in thymic epithelial tumors. (1998) (19)
- Surgical Outcomes of Lung Cancer in Patients with Combined Pulmonary Fibrosis and Emphysema (2015) (19)
- Consensus for HER2 alterations testing in non-small-cell lung cancer (2022) (18)
- Proliferating cell nuclear antigen may be superior to argyrophilic nucleolar organizer regions in predicting shortened survival of patients with non-small cell lung cancer. (1995) (18)
- Neuroendocrine tumor metastasis to the thyroid gland (2007) (18)
- p53 mutations of lung cancer are not significantly affected by CYP1A1 or GSTM1 polymorphisms. (1997) (18)
- Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study (2020) (18)
- Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC). (2019) (18)
- Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation‐positive advanced non‐small cell lung cancer (aNSCLC): 134O_PR (2016) (17)
- Pulmonary metastasectomy for gastric cancer: a 13-year single-institution experience (2013) (17)
- Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2 (2016) (17)
- Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy (2020) (17)
- P2.16-03 CheckMate 816: A Phase 3 Trial of Neoadjuvant Nivolumab Plus Ipilimumab or Chemotherapy vs Chemotherapy in Early-Stage NSCLC (2018) (17)
- The Value of Early Depth of Response in Predicting Long‐Term Outcome in EGFR‐Mutant Lung Cancer (2018) (17)
- Detection and sequencing of p53 gene mutations in bronchial biopsy samples in patients with lung cancer. (1993) (17)
- Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial. (2014) (16)
- Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of acquired resistance using molecular beacons. (2010) (16)
- Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI (2017) (16)
- 1348POverall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies (2017) (16)
- Subcategorization of resectable non-small cell lung cancer involving neighboring structures. (2008) (16)
- Factors involved in lymph node metastasis in clinical stage I non-small cell lung cancer--from studies of 604 surgical cases. (2007) (16)
- A randomised phase II trial of preoperative chemotherapy of cisplatin–docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG 0204) (2008) (16)
- Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations (2010) (16)
- Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment. (2021) (15)
- An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. (2012) (15)
- Transformation by v-H-ras does not restore proliferation of a set of temperature-sensitive cell-cycle mutants of rat 3Y1 fibroblasts. (1990) (15)
- Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors (2021) (15)
- Mutations in dominant and recessive oncogenes, and the expression of opioid and nicotine receptors in the pathogenesis of lung cancer (1991) (15)
- Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion. (2015) (15)
- Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women. (2019) (15)
- Prognostic implication of the EGFR gene mutations in a large cohort of Japanese patients with early stage lung adenocarcinoma (2007) (15)
- Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L). (2012) (14)
- Stepwise examination for differential diagnosis of primary lung cancer and breast cancer relapse presenting as a solitary pulmonary nodule in patients after mastectomy (2008) (14)
- Successful management of tracheo-innominate artery fistula using interposition of a thymus pedicle flap (1995) (14)
- Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression (2016) (14)
- Thoracoscopy in the management of intrathoracic neurogenic tumors. (1996) (14)
- Design and Rationale for a Phase III, Double-blind, Placebo-controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small-cell Lung Cancer: The AEGEAN Trial (2021) (14)
- Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non‐small‐cell lung cancer for gefitinib treatment (2009) (14)
- Frameshift mutations in TGFbetaRII, IGFIIR, BAX, hMSH3 and hMSH6 are absent in lung cancers. (1999) (14)
- Significance of the serum carcinoembryonic antigen level during the follow-up of patients with completely resected non-small-cell lung cancer. (2014) (14)
- A Randomized Phase II Study Comparing Nivolumab With Carboplatin‐Pemetrexed for Patients With EGFR Mutation–Positive Nonsquamous Non–Small‐Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Stud (2017) (14)
- DNA polymerase‐α as a putative early relapse marker in non‐small cell lung cancer. An immunohistochemical study (1991) (14)
- Malignant transformation of an intrathoracic neurofibroma in von Recklinghausen's disease. (1998) (13)
- Randomized phase III study of pemetrexed/cisplatin (Pem/Cis) versus vinorelbine /cisplatin (Vnr/Cis) for completely resected stage II-IIIA non-squamous non-small-cell lung cancer (Ns-NSCLC): The JIPANG study. (2019) (13)
- Analysis of β-tubulin gene alteration in human lung cancer cell lines (2003) (13)
- Gefitinib combined survival analysis of the mutation positives from the prospective phase II trials (I-CAMP) (2008) (13)
- Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study. (2010) (13)
- Lack of Association between the BIM Deletion Polymorphism and the Risk of Lung Cancer with and without EGFR Mutations (2015) (13)
- Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status (2017) (13)
- RASSF3 downregulation increases malignant phenotypes of non-small cell lung cancer. (2014) (13)
- Serum carcinoembryonic antigen level as a surrogate marker for the evaluation of tumor response to chemotherapy in nonsmall cell lung cancer. (2010) (13)
- Validation of a Nomogram for Predicting Overall Survival After Resection of Pulmonary Metastases from Colorectal Cancer at a Single Center (2010) (13)
- Clinical aspects of multimodality therapy for resectable locoregional esophageal cancer. (2006) (12)
- Interferon-gamma differentially regulates susceptibility of lung cancer cells to telomerase-specific cytotoxic T lymphocytes. (2004) (12)
- Controversy about Small Peripheral Lung Adenocarcinomas: How Should We Manage Them? (2007) (12)
- Increased levels of serum intercellular adhesion molecule-1 (ICAM-1) in patients with non-small cell lung cancer. (1996) (12)
- Risk assessment of perioperative mortality after pulmonary resection in patients with primary lung cancer: the 30- or 90-day mortality (2014) (12)
- Collateral Chemoresistance to Anti-Microtubule Agents in a Lung Cancer Cell Line with Acquired Resistance to Erlotinib (2015) (12)
- CT and MRI manifestations of primary pulmonary plasmacytoma. (1995) (12)
- Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines (2017) (12)
- Adenocarcinoma and squamous cell carcinoma in the same lobe of the lung. A case report. (1991) (12)
- Time to first cigarette and lung cancer risk in Japan. (2013) (12)
- Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer. (2017) (12)
- Abortive transformation of temperature‐sensitive mutants of rat 3Y1 cells by simian virus 40: Effect of cellular arrest states on entry into S phase and cellular proliferation (1985) (12)
- A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing (2019) (12)
- Combined thoracoscopy and mediastinoscopy for the evaluation of mediastinal lymph node metastasis in left upper lobe lung cancer. (1994) (12)
- Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. (2020) (12)
- Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations (2021) (12)
- Phenotypic characterization of lymphokine-activated killer cells from human lymph node lymphocytes. (1989) (12)
- Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers. (2012) (11)
- Identification of an epitope from the epithelial cell adhesion molecule eliciting HLA-A*2402-restricted cytotoxic T-lymphocyte responses. (2004) (11)
- Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer (2020) (11)
- Evaluation of radiologic diagnosis in peripheral clinical IA lung cancers-A prospective study for radiological diagnosis of peripheral early lung cancer (JCOG 0201). (2006) (11)
- Performance of Oncomine Fusion Transcript kit for formalin‐fixed, paraffin‐embedded lung cancer specimens (2019) (11)
- Adjuvant therapy of operable nonsmall cell lung cancer: an update (2020) (11)
- MA07.03 Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J-ALEX) (2017) (11)
- Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial. (2021) (11)
- CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation. (2014) (11)
- Characteristics of non‐small cell lung cancer 3 cm or less in diameter (1995) (11)
- Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas (2019) (11)
- Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. (2022) (11)
- Recent evidence, advances, and current practices in surgical treatment of lung cancer. (2014) (11)
- Survival following resection for lung cancer as a second primary cancer. (1995) (10)
- Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance (2021) (10)
- Prognostic Implication of Predominant Histologic Subtypes of Lymph Node Metastases in Surgically Resected Lung Adenocarcinoma (2014) (10)
- Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review (2021) (10)
- Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy‐Naive Isogenic Lung Cancer Lesions with EGFR Mutation (2016) (10)
- An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer. (2015) (10)
- Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors. (2011) (10)
- Chemosensitivity testing of human lung cancer tissues using the succinate dehydrogenase inhibition test. (1990) (9)
- Aspergilloma within cavitating pulmonary carcinoma. Case report. (1993) (9)
- Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making? (2020) (9)
- Estradiol sensitivity test using contact-sensitive plates of confluent BALB/c 3T3 cell monolayers. (1990) (9)
- 9002 A phase III, first-line trial of gefitinib versus cisplatin plusdocetaxel for patients with advanced or recurrent non-small cell lungcancer (NSCLC) harboring activating mutation of the epidermal growthfactor receptor (EGFR) gene: a preliminary results of WJTOG 3405 (2009) (8)
- Video-assisted thoracoscopic surgery of bullous and bleb disorders of the lung using endoscopic stapling device. (1995) (8)
- Angiosarcoma of the chest wall with a gastric metastasis. (1993) (8)
- Benign tumors and tumor-like lesions of the lung. (1990) (8)
- Analysis of ERBB4 Mutations and Expression in Japanese Patients with Lung Cancer (2010) (8)
- Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC). (2021) (8)
- Prognostic value of plasma fibrinogen and d-dimer levels in patients with surgically resected non-small cell lung cancer (2020) (8)
- Surgical resection for pulmonary metastases of sweat gland carcinoma. (1994) (8)
- Abstract 2101A: CNX-2006, a novel irreversible epidermal growth factor receptor (EGFR) inhibitor, selectively inhibits EGFR T790M and fails to induce T790M-mediated resistancein vitro. (2013) (7)
- Giant hamartoma of the lung with a high production of carbohydrate antigen 19-9. (1993) (7)
- Polymorphism of dihydropyrimidine dehydrogenase (DPYD) Cys29Arg and risk of six malignancies in Japanese. (2005) (7)
- Clinical outcome of node‐negative oligometastatic non–small cell lung cancer (2016) (7)
- p 27 KIP 1 in Human Lung Cancers : Differential Changes in Small Cell and Non-Small Cell Carcinomas 1 (2006) (7)
- Genetic and Prognostic Differences of Non-small Cell Lung Cancer between Elderly Patients and Younger Counterparts. (2012) (7)
- Solitary pulmonary metastasis from lung cancer harboring EML4-ALK after a 15-year disease-free interval. (2013) (7)
- Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study (2021) (7)
- Comparison of high sensitive IHC, FISH, and RT-PCR direct sequencing for detection of ALK translocation in lung cancer. (2011) (7)
- Genetic analysis of the catalytic domain of the GAP gene in human lung cancer cell lines (2004) (7)
- Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L). (2021) (6)
- Prognostic impact of pleural lavage cytology in patients with primary lung cancer. (2016) (6)
- Combined resections of the diaphragm and the liver for a locally advanced non-small-cell lung cancer. (1996) (6)
- [Mutations of ras and p53 genes in human non-small cell lung cancer cell lines and their clinical significance]. (1992) (6)
- Immunohistochemical evidence of the epidermal growth factor receptor in human pulmonary adenocarcinoma (1990) (6)
- Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-Letter. (2016) (6)
- Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer. (2020) (6)
- Effects of sodium n-butyrate on entry into S phase in resting rat 3Y1 cells infected with simian virus 40 (1985) (6)
- Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven? (2016) (6)
- Pulmonary dirofilariasis causing a solitary lung mass and pleural effusion. (1991) (6)
- Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond (2013) (6)
- Mutational Events in Lung Cancer: Present and Developing Technologies (2018) (6)
- Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells. (2018) (6)
- Phase II study of erlotinib plus tivantinib in patients with EGFR-mutation–positive NSCLC who failed in immediately previous EGFR-TKI therapy. (2014) (6)
- Clinico-pathologic features of lung cancer with EML4-ALK translocation. (2010) (6)
- Dacomitinib: another option for EGFR-mutant lung cancer? (2014) (5)
- Racial differences in lung cancer genetics. (2015) (5)
- The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer. (2004) (5)
- Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers—Applications and Limitations (2021) (5)
- Prognosis and segment-specific nodal spread of primary lung cancer in the right lower lobe (2015) (5)
- Nucleolar organizer regions are independently associated with a shortened survival in patients with non-small cell lung cancer. (1993) (5)
- Aggressive pulmonary metastasectomies for synovial sarcoma. (1997) (5)
- Segmentectomy Versus Lobectomy in Small-Sized Peripheral Non-Small Cell Lung Cancer (JCOG0802/WJOG4607L): A Multicentre, Randomised, Controlled, Phase 3 Trial (2021) (5)
- 3113 AZD9291 in pre-treated patients with T790M positive advanced non-small cell lung cancer (NSCLC): Pooled analysis from two Phase II studies (2015) (5)
- [Delayed traumatic hernia diagnosed with magnetic resonance imaging]. (1997) (5)
- Frequent loss of the short arm of chromosome 9 in resected non-small-cell lung cancers from Japanese patients and its association with squamous cell carcinoma (2005) (5)
- Abstract 1791: CO-1686, a novel mutant-selective EGFR inhibitor, overcomes T790M mediated resistance in Non-Small Cell Lung Cancer (NSCLC) (2012) (4)
- Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five Cases. (2020) (4)
- Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer. (2021) (4)
- Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer (2022) (4)
- Mutational analysis of the EGFR gene in lung cancer with acquired resistance to gefitinib. (2006) (4)
- Clinical Implications of p 53 Autoantibodies in the Sera of Patients With Non-Small-Cell Lung Cancer (1998) (4)
- [A carcinoma arising from benign pleomorphic adenoma of the trachea]. (1997) (4)
- A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study) (2021) (4)
- Progression after spontaneous regression in lung large cell neuroendocrine carcinoma: Report of a curative resection (2015) (4)
- Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies (2019) (4)
- Analysis of beta-tubulin gene alteration in human lung cancer cell lines. (2003) (4)
- [Translational research on lung cancer--EGFR gene mutation]. (2005) (4)
- Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB–IIIA non-small cell lung cancer (WJTOG0101) (2021) (4)
- Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation (2022) (4)
- [Driver gene mutation and targeted therapy of lung cancer]. (2013) (3)
- The impact of EGFR mutation and smoking status on non-small-cell lung cancer patients treated with geftinib: A5-04 (2007) (3)
- [Genetic abnormalities in lung cancer and their prognostic implications]. (1996) (3)
- Lymph node metastasis of an esophageal cancer behind the thoracic descending aorta (2010) (3)
- Lung adenocarcinoma is more sensitive than gastric adenocarcinoma to anticancer drugs in vitro. (1991) (3)
- [Molecular targeted therapy--non-small-cell lung cancer and gefitinib]. (2005) (3)
- EGFR gene mutations: is it prognostic or predictive in surgically resected lung cancer? (2012) (3)
- Life-threatening complications after pulmonary resection for lung cancer in patients on chronic hemodialysis (2019) (3)
- EGFR genomic gain in Japanese non-small cell lung cancer patients treated with gefitinib. (2006) (3)
- PL02.09 International Association for the Study of Lung Cancer (IASLC) Study of the Impacts of COVID-19 on International Lung Cancer Clinical Trials (2021) (3)
- Video-assisted thoracoscopic surgery for spontaneous pneumothorax (1996) (3)
- Transformation by viral oncogenes increased sensitivity to heat in rat 3Y1 fibroblasts. (1993) (3)
- Unintentional Weakness of Cancers: The MEK–ERK Pathway as a Double-Edged Sword (2013) (3)
- Abstract 7: Knockdown ofEGFRto investigate its therapeutic potential for treatment of non-small cell lung cancers (2012) (3)
- P1.03-005 Phase 2 Study of Ceritinib in Patients with ALK+ NSCLC with Prior Alectinib Treatment in Japan: ASCEND-9 (2017) (3)
- Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte‐ColONy Stimulating Factor Support for Elderly Patients With Advanced Non–small‐cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L) (2018) (3)
- [Small-molecule tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR)]. (2009) (3)
- Hepatic inflow vessels caliber as an index for liver function. (1996) (3)
- Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance. (1994) (3)
- Comparison of methods for placing and managing a silastic drain after pulmonary resection. (2009) (3)
- Seven-year follow-up of preoperative chemoradiotherapy in superior sulcus tumor: Report of a Japan Clinical Oncology Group Trial (JCOG9806). (2010) (2)
- Utility of the Ba/F3 cell system for exploring on‐target mechanisms of resistance to targeted therapies for lung cancer (2022) (2)
- A resected case of large-cell neuroendocrine carcinoma of the thymus (2015) (2)
- The Effect of Gefitinib on B-RAF Mutant Non-small Cell Lung Cancer and Transfectants (2007) (2)
- Surgical therapy for pulmonary metastasis of breast cancer (2020) (2)
- Non-Small Cell Lung Cancer Cell Lines1 (1996) (2)
- A randomized phase II trial of pre-operative docetaxel and cisplatin (DP) or docetaxel alone (D) in clinical (c-) stage IB/II non-small cell lung cancer (NSCLC): Initial report of Japan Clinical Oncology Group trial (JCOG 0204) (2005) (2)
- International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials (2022) (2)
- EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence (2012) (2)
- Adjuvant Chemotherapy in Patients with Completely Resected Lung Cancer: Investigation of the Current Situation After Publication of the Second Edition of Clinical Practice Guidelines for Lung Cancer (2010) (2)
- Integrin-linked kinase pathway in heterogeneous pulmonary sarcomatoid carcinoma. (2021) (2)
- M03-01: Molecular predictors of EGFR-TKIs (2007) (2)
- Combined bevacizumab and erlotinib treatment in patients with lung cancer with the T790M resistance mutation. (2017) (2)
- Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial (2022) (2)
- MA15.11 Acquired Resistance Mechanisms to EGFR Kinase Inhibitors Alter PD-L1 Expression Status in Lung Cancer (2017) (2)
- A suture granuloma of the lung that occurred 19 years after surgery for mucoepidermoid tumor (2009) (2)
- Phase II study of erlotinib plus tivantinib ( ARQ 197 ) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI , ge fi tinib or erlotinib (2016) (2)
- Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor (2021) (2)
- [Molecular Biology for Surgical Treatment of Lung Cancer]. (2017) (2)
- A Double Role in Lung Cancer Cell Survival? (2008) (2)
- The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgery (2021) (2)
- [Serum levels of c-erbB-2 protein in patients with lung adenocarcinoma: preliminary report]. (1993) (2)
- [Gefitinib and epidermal growth factor receptor gene mutation]. (2007) (2)
- A multicenter, open label, randomized phase III study of atezolizumab with platinum-pemetrexed and with or without bevacizumab for patients with advanced nonsquamous non-small cell lung cancer (WJOG11218L APPLE Study). (2019) (2)
- Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization: PD6-2-2 (2007) (2)
- Dorsal mass in hyperparathyroidism secondary to chronic renal failure. (1989) (1)
- [Feasibility and response of gemcitabine and carboplatin biweekly combination chemotherapy for patients with postoperative recurrence non-small cell lung cancer]. (2009) (1)
- [Development of molecular targeted therapies in lung cancers]. (2014) (1)
- Phase III study of induction chemotherapy (docetaxel and carboplatin) with or without radiotherapy followed by surgery in patients with stage IIIA (pN2) non-small cell lung cancer (NSCLC): WJTOG9903. (2009) (1)
- Abstract 718: Acquired epithelial-mesenchymal transition like feature in anEGFR-mutant lung cancer cell line with acquired resistance to erlotinib (2011) (1)
- Frequent EGFR Mutations and Better Prognosis in Positron Emission Tomography-Negative, Solid-Type Lung Cancer. (2021) (1)
- Changes in survival of patients with non–small cell lung cancer in Japan: An interrupted time series study (2022) (1)
- New TNM Classification for Non-small Cell Lung Cancer by Evaluating T Factor Based on Tumor Size and Visceral Pleural Invasion (2007) (1)
- 1079 A phase II trial of chemoradiotherapy followed by surgery in pancoast tumors: Initial report of the Japan Clinical Oncology Group trial (JCOG 9806) (2003) (1)
- Chemosensitivity and clinical features of EML4-ALK-positive patients with advanced non-small cell lung cancer. (2012) (1)
- Different chemosensitivities of rat 3Y1 fibroblasts transformed by various agents in vitro. (1991) (1)
- Adjusted indirect comparison using propensity score matching of osimertinib to doublet chemotherapy in patients with EGFRm T790M NSCLC who have progressed after EGFR-TKI (2016) (1)
- P2.04-15 Heterogeneity and Correlation Between Immune Markers in Lung Cancers: Analysis of Treatment-Naïve Lesions (2018) (1)
- IS4. Trials in Progress (2012) (1)
- [Genetic alteration of lung cancer as a prognostic marker and its therapeutic implications]. (1997) (1)
- Expert consensus recommendations on biomarker testing in metastatic and non-metastatic non-small cell lung cancer in Asia. (2022) (1)
- Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: An epidemiological evaluation in Japan (2006) (1)
- Driver oncogene mutations and personalized treatment of lung cancer (2013) (1)
- [Postoperative adjuvant chemotherapy for lung, gastric, colorectal and breast cancers]. (2010) (1)
- Identifying patients with peripheral-type early non-small cell lung cancer (T1N0M0) for whom irradiation of the primary focus alone could lead to successful treatment. (2008) (1)
- Screening Test for Hormone Sensitivity by the Autoradiographic Method Using Cell Mats (1990) (1)
- Papillary carcinoma in a huge intrathoracic goiter with tracheal stenosis and invasion. Case report. (1993) (1)
- P3-106: Analysis of the relationship between the mutations of the EGFR and response to gefitinib treatment in patients with recurrent lung cancer after pulmonary resection; updated analysis (2007) (1)
- D2-07: Mechanisms of activating PI3K signaling in lung cancers that become resistant EGFR tyrosine kinase inhibitors (2007) (1)
- Calcified Lymph Node Metastases in Bronchial Gland Cell Type Adenocarcinoma of The Lung (1995) (1)
- Molecular biology of lung cancer (2010) (1)
- Mass Screening and Molecular Diagnosis for Lung Cancer (2005) (1)
- Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial. (2023) (1)
- Hepatocyte growth factor as inducer of gefitinib resistance in non-small cell lung cancer harboring EGFR activating mutations. (2009) (1)
- The sensitivity of hyperthermo-chemo-radiotherapy for neoplastic cells in vitro on contact-sensitive plates. (1993) (1)
- BRAF Fusion - Another Mechanism of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. (2019) (1)
- Abstract 2200: Potent in vitro activity of Tarloxotinib for EGFR C797S and other mutations refractory to current EGFR tyrosine kinase inhibitors (2019) (1)
- Ground glass nodules with 5 years' stability can grow after 10-year follow-up: do genetic features determine the fate? (2019) (1)
- Smoking-related and non-smoking-related carcinogensis in adenocarcinoma of the lung (2008) (1)
- Confluent BALB/c 3T3 cells monolayer provides selective and efficient growth of neoplastic cells. (1990) (1)
- Lung Adenocarcinoma Coexistent with Pulmonary Non-tuberculous Mycobacteriosis (2012) (1)
- 9008 ORAL Randomized Phase III Trial of Adjuvant Chemotherapy With Gemcitabine Compared With Oral Tegafur-uracil (UFT) in Resected, Stage IB-llla Non-small Cell Lung Cancer (WJTOG 0101) (2011) (1)
- Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC (2022) (1)
- Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405) (2022) (1)
- S-1 as an option for second-line treatment of NSCLC. Is the 'East Side Story' applicable in the West? (2017) (1)
- Phase III Study of Cisplatin Plus Pemetrexed versus Cisplatin Plus Vinorelbine for Completely Resected Stage II-IIIA Non-Squamous Non-Small-Cell Lung Cancer: The JIPANG Study (2019) (1)
- PTEN – A MOLECULE THAT CANCERS ABUSE (2013) (1)
- The Significance of Changes in Serum CEA Level as a Surrogate Marker for Evaluating Tumor Response to Chemotherapy in Non-small Cell Lung Cancer (1)
- P-648 EGFR and Ki-ras mutations in pulmonary adenosquamous carcinoma (2005) (1)
- Importance of doctor‐initiated management of the balance between work and treatment for lung cancer patients: Results of a nationwide survey by the Japan Lung Cancer Society (2020) (1)
- 932MO Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816 (2022) (1)
- PS06.01 CD44 Confers EMT Phenotypic Change Following Resistance to EGFR-TKIs in Lung Cancer: Topic: Pathology (2017) (1)
- [Effect of the continuous epidural saline infusion for patients with postdural puncture headache after pulmonary resection]. (2011) (1)
- Abstract 4468: Cripto-1 elicits innate resistance to EGFR inhibitors in non-small cell lung cancer harboring EGFR-sensitizing mutations. (2013) (1)
- 臨床IA期末梢型非小細胞肺癌における放射線学的診断の評価:末梢型早期肺癌の放射線学的診断の前向き研究(JCOG0201) (2006) (1)
- Combined carboplatin and cisplatin therapy in patients with advanced non-small cell lung cancer. (1997) (1)
- A case of typical bronchial carcinoid with lymph node relapse 30 years after the initial operation (2007) (1)
- 72PD LOBECTOMY IN COMBINATION WITH RADICAL LYMPHADENECTOMY IS THE MOST FREQUENT SURGICAL INTERVENTION PERFORMED IN PATIENTS RANDOMIZED IN MAGRIT TRIAL EVALUATING MAGE-A3 ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT TREATMENT IN STAGE IB IIIA NSCLC (2011) (1)
- Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosis (2019) (0)
- [Molecular diagnosis in lung cancer]. (2002) (0)
- EP08.02-085 In vitro Activity and Potential Resistance Mutations Against BI-4020, a 4th-generation EGFR-TKI (2022) (0)
- Role of ctDNA in the Management of Patients with Resected Lung Cancer (2022) (0)
- ES28.01 Biology of KRAS Targeting Agents (2021) (0)
- [Expression of CD44 alternative splicing variants in lung cancer]. (1995) (0)
- Abstract 2052: Tumor mutation burden as a biomarker of relapse free survival of non-squamous non-small cell lung cancer treated with PEM/CDDP in adjuvant setting (the JIPANG-TR) (2020) (0)
- [Molecular biology in diagnosis and treatment of lung cancer]. (2007) (0)
- The History and Current State of EGFR-TKIs (2017) (0)
- Cavernous lymphangioma extending to the posterior mediastinum and the retroperitoneum ; a case report (1992) (0)
- O-043 A randomized phase II trial of pre-operative docetaxel and cisplatin (DP) or docetaxel alone (D) in clinical (c-) stage IB/II nonsmall cell lung cancer (NSCLC): Initial report of Japan Clinical Oncology Group trial (JCOG 0204) (2005) (0)
- Advances in Brief Population-based Mapping of Pulmonary Adenoma Susceptibility 1 Locus 1 (2000) (0)
- 1207PANTITUMOR ACTIVITY OF BEVACIZUMAB COMBINED WITH ERLOTINIB IN T790M RESISTANCE MUTATION POSITIVE NON-SMALL CELL LUNG CANCER XENOGRAFT MODELS. (2014) (0)
- Event-free survival (EFS) with neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo by surgical outcomes in resectable non-small cell lung cancer (NSCLC) from CheckMate 816 (2023) (0)
- P-360 hTERT-specific CTL lysed lung cancer cell lines in an HLA-A24 restricted fasion (2003) (0)
- Lack of predictive value of reticulocalbin-1 and GST-Pai alterations for efficacy of postoperative adjuvant chemotherapy consisting of cisplatin plus vindesine in patients with p-stage IIIA-N2 non-small cell lung cancer (NSCLC) (JCOG9304A) (2005) (0)
- Long term survivors with palliative resection for non-small cell lung cancer (1990) (0)
- Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas. (2021) (0)
- Corrigendum to 'Consensus for HER2 Alterations Testing in Non-small Cell Lung Cancer': [ESMO Open Volume 7 Issue 1 (2022) 100395]. (2022) (0)
- Other Primary Malignancies in Patients with Esophageal Cancer (2011) (0)
- EGFR mutations in non-small-cell lung cancer – Authors' reply (2010) (0)
- P3.02b-120 EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib (2017) (0)
- P2.08-007 Listen Advocate Voice - Web-Survey for the Japanese Model of Lung Cancer Advocacy by Society: Topic: Patient’s Voice, Patient’s Information (2017) (0)
- Original Article Serum Carcinoembryonic Antigen Level as a Surrogate Marker for the Evaluation of Tumor Response to Chemotherapy in Nonsmall Cell Lung Cancer (2010) (0)
- Abstract IA5: Genetic and genomic difference in lung cancer based on ethnicity (2012) (0)
- Combined TherapywithMutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer (2012) (0)
- [Immune-Checkpoint Inhibitors for Lung Cancer with EGFR Mutation]. (2017) (0)
- Molecular Markers in Diagnosis and Therapy of Lung Cancer. (2002) (0)
- Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer. (2023) (0)
- A Case of Recurrent Pulmonary Artery Intimal Sarcoma After Left Pneumonectomy (2015) (0)
- Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives (2023) (0)
- Abstract 1209: Detection of EGFR T790M mutation in non-small-cell lung cancer patients using colony hybridization assay (2012) (0)
- P1-068: Comparison of RECIST, WHO criteria, and serum CEA for evaluation of tumor response to chemotherapy in non-small cell lung cancer (2007) (0)
- Abstract 3255: Probing and overcoming KRASG12C inhibitor resistance by combination with a pan-KRAS SOS1 inhibitor (2022) (0)
- P68.12 Inter-Tumor Heterogeneity of CD44 Expression in Non-Small Cell Lung Cancers / EGFR Mutated Lung Adenocarcinomas (2021) (0)
- 患者・医師アンケートから浮き彫りになった，医師主導で行う就労を意識した肺癌マネージメントの重要性 (2020) (0)
- Clinical impact of targetable gene alterations on therapeutic outcomes in stage II/III locally advanced non-small cell lung cancer patients. (2020) (0)
- P1.13-42 Activity of Novel HER2 Inhibitor, Poziotinib, for HER2 Exon 20 Mutations in Lung Cancer and Mechanism of Acquired Resistance (2018) (0)
- Tokuda Akihiro Tomida Shinya Toyokuni Hitoshi Tsuda Shoichiro Tsugane Tatsuhiko Tsunoda Heiichiro Udono Koji Ueda Yoshimasa Uehara Hiroo Ueno Kazuo Umezawa Toshikazu Ushijima Toshihiko Wakabayashi Kenji Wakai Tetsuro Watabe (2016) (0)
- S02.04 Dr. Gazdar as a Mentor (2019) (0)
- Vinorelbine Plus Cisplatin Versus Gefitinib in Resected Non-Small-Cell Lung Cancer Haboring Activating EGFR Mutation (WJOG6410L) (2012) (0)
- 39IN BEYOND EGFR, KRAS, ALK; WHAT ELSE? (2011) (0)
- Attention Study: Asian Trial of Tivantinib Plus Erlotinib Versus Erlotinib for NSCLC without EGFR Mutation; a Phase 3 Trial with a Personalized Dose Setting Based on Pretreatment Test for CYP2C19 Polymorphism (2012) (0)
- 3016 Receptor tyrosine kinase mutations in non-small cell lung cancer (2015) (0)
- PD6-2-2: Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization (2007) (0)
- Corrigendum to "Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer" [Lung Cancer 121 (July) (2018) Pages 37-40]. (2019) (0)
- In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial. (2021) (0)
- Metastatic pulmonary tumor from type 3 gastric neuroendocrine tumor (2021) (0)
- 84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816 (2023) (0)
- Clinical features of patients who required re-hospitalization after pulmonary resection (2007) (0)
- P1.02-047 Effect of Dasatinib on EMT-Mediated-Mechanism of Resistance against EGFR Inhibitors in Lung Cancer Cells: Topic: Driver Genes in NSCLC, Resistance, and Other (2017) (0)
- Stefan Wuchty , of Knowledge The Increasing Dominance of Teams in Production (2009) (0)
- O-229 Prognostic value of cytokeratin-positive cells in the bone marrow and lymph nodes of patients with resected non-small cell lung cancer: a multicenter prospective study (2003) (0)
- ES 08.01 Overview of Diagnostics and Pathology (2017) (0)
- A process for classifying the strength of gene expression in lung cancer tissues. (2004) (0)
- Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia (2022) (0)
- Institutional report - Thoracic non-oncologic Comparison of methods for placing and managing a silastic drain after pulmonary resection (2009) (0)
- Oncogenic driver mutations (2012) (0)
- Prognostic Role of Preoperative FDG-PET/CT with an Image-based Harmonization Technique - A Multicenter Retrospective Study (2023) (0)
- Abstract B53: Time to first cigarette and lung cancer risk in Japan (2013) (0)
- EGFR mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma (2009) (0)
- P86.05 In Vitro Validation Study for HER2 Mutations Identified in Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial (2021) (0)
- Biomarker Research in Lung Cancer and its Future in Japan (2012) (0)
- [Current Status and Future Perspectives of Molecular Targeted Therapies for Lung Cancer]. (2022) (0)
- Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules (GGN): Differences between those with growth potential and those without. (2014) (0)
- 931MO Final overall survival analysis of phase III study of pemetrexed/cisplatin versus vinorelbine/cisplatin for completely resected non-squamous non-small cell lung cancer: The JIPANG Study (2022) (0)
- 124P Phase II study of neoadjuvant concurrent chemo-immuno-radiation therapy followed by surgery and adjuvant immunotherapy for resectable stage IIIA-B N2 non-small cell lung cancer: SQUAT trial (WJOG 12119L) (2022) (0)
- O3–096BIOMARKER ANALYSIS OF WJOG4107 (A RANDOMIZED PHASE II TRIAL OF ADJUVANT CHEMOTHERAPY WITH S-1 VS CDDP + S-1 IN NSCLC) (2013) (0)
- Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL). (2023) (0)
- Clinical features in surgically treated patients with small cell lung cancer: Risk of brain metastasis and possible role of prophylactic cranial irradiation. (2010) (0)
- Abstract. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are efficacious drugs for non‐small cell lung cancers (NSCLCs) with EGFR‐activating mutations. Afatinib, a second-generation EGFR-TKI and osimertinib, a third-generation EGFR-TKI, are both standard therapies for patien (2018) (0)
- JIPANG study: Randomized phase III study of pemetrexed/cisplatin (PEM/Cis) versus vinorelbine /cisplatin (VNR/Cis) for completely resected p-stage II-IIIA non-squamous non-small cell lung cancer (Ns-NSCLC): Outcomes based on EGFR mutation status (2019) (0)
- Five-year follow-up of preoperative chemotherapy (Cx) of docetaxel with or without cisplatin for clinical (c-) stage IB/II non-small cell lung cancer (NSCLC): Report of a Japan Clinical Oncology Group study (JCOG0204). (2010) (0)
- E46. Clinical and biological implications of epidermal growth factor receptor (EGFR) gene mutations and gefitinib treatment for NSCLC (2005) (0)
- [Acquired resistance mechanisms to EGFR-TKIs in EGFR mutated lung cancers]. (2012) (0)
- Mediastinal tumors associated with von Recklinghausen's disease (1992) (0)
- Mutations in the Epidermal Growth Factor Receptor Gene And Sensitivity to Tyrosine Kinase Inhibitors (2006) (0)
- Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation—diversity, ductility, and destiny (2012) (0)
- PL01.03 Will the Immunotherapy with Newer Biomarkers, Combination Therapy or New Technology Eventually Cure Lung Cancer? (2019) (0)
- Iconographies supplémentaires de l'article : Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer? (2011) (0)
- Reply to the letter to the editor ‘ Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patients (2015) (0)
- MA 05.04 Distinct Immunosuppressive Microenvironment Determines Poor Prognosis of Nonsmokers with Adenocarcinoma of Non-Small Cell Lung Cancer (2017) (0)
- P2.17-41 Treatment Outcomes of Pulmonary Resection in NSCLC Patients with Autoimmune Diseases (2019) (0)
- [A case of postoperative hyponatremia caused by Sheehan syndrome associated with lung carcinoma]. (1995) (0)
- Propensity score analysis for the efficacy of preoperative antibiotics in patients with resected primary lung cancer: Levofloxacin versus cefazolin (2022) (0)
- P3.02-059 T790M and C797S as Mechanisms of Acquired Resistance to Dacomitinib in Cell Models (2017) (0)
- The close relationship between growth factors and the nucleolar organizer regions in adenocarcinoma of the lung. (1995) (0)
- SC04.02 Management of Resistance to EGFR Tyrosine Kinase Inhibitors (2017) (0)
- iprocal and Complementary Role of MET Amplification EGFR T 790 M Mutation in Acquired Resistance R inase Inhibitors in Lung Cancer (2010) (0)
- Two Cases of Pulmonary Adenocarcinoma in Situ Resected After 9 and 12 Years’ Follow-up (2018) (0)
- Subjective Visual Comparison and Surgical-Pathological Correlation of MRI and CT in Preoperative Evaluation of Lung Cancer. (1992) (0)
- [p53 tumor suppressor gene and its clinical significance]. (1992) (0)
- S-1 as an option for second-line treatment of NSCLC. Is the 'East Side Story' applicable in the West? (2017) (0)
- P1.04-55 Comparison of PD-L1 Expression Status Between Pure-Solid Versus Part-Solid Tumors in Lung Adenocarcinomas (2019) (0)
- Factors Affecting Postoperative Recurrence in Patients with Pathological Stage IB Non-small-cell Lung Cancer (2007) (0)
- P1.01-34 Docetaxel Plus Ramucirumab with Prophylactic PEG-G-CSF Support for Chemo-NaïVe Elderly NSCLC Patients: A Phase II Study (WJOG9416L) (2018) (0)
- [A Case of Resected Superior Sulcus Tumor with Pathological Complete Response after Trimodality Therapy]. (2018) (0)
- Proliferating cell nuclear antigen and argyrophilic nucleolar organizer regions in patients with thymic disease. (1997) (0)
- Natural History of Small Lung Lesions with Ground-glass Opacity: P1-061 (2007) (0)
- A rare case of thymic tuberculosis undergoing surgical resection for an anterior mediastinal tumor (2016) (0)
- Latest innovations in NSCLC management (2012) (0)
- 〈Review〉Driver oncogene mutations and personalized treatment of lung cancer (2013) (0)
- Neighboring Structures Subcategorization of Resectable Non-Small Cell Lung Cancer Involving (2013) (0)
- SerumLevel andTissueExpression of c-erbB-2 Protein inLung Adenocarcinoma" (2015) (0)
- F-082SIGNIFICANCE OF SERUM CARCINOEMBRYONIC ANTIGEN AT THE FOLLOW-UP OF COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER (2013) (0)
- P04.01 Presence of Ground Glass Opacity Component is True Determinant of Prognosis in Clinical Stage I Non-Small Cell Lung Cancer (2021) (0)
- P2.03a-009 Clinical Outcome of Node-Negative Oligometastatic Non-Small Cell Lung Cancer: Topic: Clinical Trials (2017) (0)
- P76.71 RYK Confers Drug Tolerance to Osimertinib in Lung Cancer Cells with EGFR Mutations (2021) (0)
- EP08.01-005 A Multicenter Prospective Observational Study of Atezolizumab in Unresectable Advanced or Metastatic NSCLC in Japan: J-TAIL (2022) (0)
- O-79 Prognostic model of pulmonary adenocarcinoma by expression profiling as determined by quantitative real-time PCR (2003) (0)
- O1-10-1Comparison of various EGFR tyrosine kinase inhibitors (TKIs) for tumors with exon 18 mutations of the EGFR gene (2015) (0)
- RELATIONSHIP BETWEEN PROGNOSIS AND NODAL MICROMETASTASIS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (2006) (0)
- SY20-4 Treatment strategy of lung cancer with MET, NTRK and BRAF gene aberrations: Insights from in vitro and clinical data (2022) (0)
- JS1. the current situation of biomarker study in japan (2012) (0)
- Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity (2015) (0)
- Local treatment of lung cancer beyond conventional concepts. (2017) (0)
- Analysis of EML4-ALK Positive Non-Small Cell Lung Cancer with Advanced Stage (2012) (0)
- Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data (2022) (0)
- JSMO Tobacco Control Action: Result of a membership survey (2019) (0)
- P1.13-41 In Vitro Evaluation for Optimal MET-TKI Selection in Lung Cancers with MET Mutations Including Exon 14 Skipping (2018) (0)
- EP08.02-146 Proposal of Foretinib as Second-Line TKI after Capmatinib/Tepotinib Treatment Failure in NSCLC with MET Exon 14 Mutation (2022) (0)
- High levels of AXL expression in untreated EGFR ‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib (2022) (0)
- Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer (2021) (0)
- clinical significance Expression of human telomerase subunit genes in primary lung cancer and its (2013) (0)
- Therapeutic Discovery Combined TherapywithMutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer (2012) (0)
- Features of prognosis, genetics and drug sensitivity of very elderly lung cancer patients. (2015) (0)
- The Importance of Doctor-initiated Lung Cancer Management for Balancing Work and Treatment Highlighted by the Results of a Nationwide Questionnaire Survey (2020) (0)
- Perioperative Treatment for the Eradication of Non-small Cell Lung Cancer (2020) (0)
- 3046 Impact of bevacizumab in combination with erlotinib on EGFRmutatant non-small cell lung cancer xenograft models with T790M mutation or MET amplification (2015) (0)
- P28-3 Epithelial-mesenchymal transition changes mitochondrial oxidative phosphorylation in the lung adenocarcinoma cells (2021) (0)
- Abstract 4583: Heterogeneity in immune biomarker expression: Detailed analysis of a case with SCLC transformation after EGFR-TKI treatment (2017) (0)
- Honoring the Past, Embracing the Present, You Are the Future. (2019) (0)
- Molecular lesions as targets for diagnosis and therapy of lung cancer. (2002) (0)
- Abstract A178: Role of tumor and host‐derived HGF in drug resistance to EGFR inhibitors in EGFR activating mutation‐positive lung cancer (2009) (0)
- Biomarker analysis of WJOG4107, a randomized phase II trial of adjuvant chemotherapy with S-1 versus CDDP+S-1 for resected stage II-IIIA non-small cell lung cancer (NSCLC). (2013) (0)
- PL03.06 The Future of Targeted Therapy (2018) (0)
- The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example (2011) (0)
- Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A (2017) (0)
- P2.03-17 EGFR T790M Mutation may not be Generated through Selection by EGFR-TKI from Randomly Occurring Mutations in Vitro Using ENU (2018) (0)
- W-I-4 Mutations of ras genes but not p53 gene in tumor cell lines established from non-small cell lung cancer (NSCLC) patients are a poor prognostic factor. (1991) (0)
- EGF receptor-targeted drugs (2011) (0)
- Lung Cancer and KRAS -Its Molecular Biology/Genetics and Therapeutic Strategy- (2022) (0)
- MA 12.07 Adjusted Indirect Comparison of Osimertinib to Chemotherapy in NSCLC Patients with EGFRm T790M Who Progressed after EGFR-TKI (2017) (0)
- A case of multiple endocrine neoplasia (MEN) type 1 detected from thymus carcinoid (2020) (0)
- [Surgical problems encountered in cases of S0 (serosal invasion-free) gastric cancers]. (1988) (0)
- Three cases of pulmonary embolism after surgery for lung cancer (2011) (0)
- Risk Assessment of Perioperative Mortality After Pulmonary Resection for Primary Lung Cancer: the 30-day or 90-day Mortality (2013) (0)
- A case of intrapulmonary solitary fibrous tumor harboring NAB2-STAT6 fusion gene (2019) (0)
- P3.16-049 Surgery with Continued TKI Therapy After Acquiring Resistance to EGFR or ALK TKI (2017) (0)
- LKB1 gene mutations are infrequent in Japanese patients with lung cancer: P2-021 (2007) (0)
- Long-term survival after hepatic resection and three pulmonary resections for metastatic hepatocellular carcinoma (2011) (0)
- Activating Mutations − Receptor Lung Adenocarcinoma with Epidermal Growth Factor Hepatocyte Growth Factor Induces Gefitinib Resistance of Updated (2008) (0)
- Prognostic and Predictive Implication of Epidermal Growth Factor Receptor Gene Mutation on Overall Survival in Non-Small Cell Lung Cancer Patients With Postsurgical Recurrence (2013) (0)
- Comparison of pain after conventional thoracotomy and video-assisted thoracoscopic surgery for spontaneous pneumothorax (1996) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Tetsuya Mitsudomi?
Tetsuya Mitsudomi is affiliated with the following schools:
